Lupus, Skin and COVID19

During the Pandemic various online webinars were given about the Psycho-Social Impacts of COVID-19 on Patients with Chronic Skin Conditions. Generally they showed that: Patients with chronic skin conditions (auto-immune disease related) using HQC have no higher risk of getting Covid. When using immune suppressants, patients should be more careful. When infected with Covid, consult […]

Hydroxychloroquine: Patient reported availability

Since Hydroxychloroquine (HcQ) has been regularly mentioned in media as a potential medication in the fight against COVID, the number of patients highlighting unavailability issues increased substantially. With the help of its members, LUPUS EUROPE initiated a survey amongst patients to obtain broad based feedback on the magnitude and impact of the issue. Results covering […]

Help usย trackย Hydroxychloroquine access issues…

Over the past weeks, LUPUS EUROPE and several of its members have worked to improve availability of Hydroxychloroquine for people with lupus in Europe, as speculations on its possible use for COVID treatment have resulted in an increased (off-label) demand. Our objective is that all patients with a chronic condition requiring Hydroxychloroquine have access, if […]

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
5 days ago
LUPUS EUROPE

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the "Info Centre" section of our website!

Don't forget to subscribe to be up to date!

www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
... See MoreSee Less

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the Info Centre section of our website! 

Dont forget to subscribe to be up to date!

https://www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
7 days ago
LUPUS EUROPE

No matter what chronic illness you're living with, having a sense of community and knowing
that you're not alone is helps your daily health and is key to staying motivated.

Follow the community over at @ThisIsLivingToday for tips and advice on wellness, mindfulness and movement. Letโ€™s fight the daily battle together.
... See MoreSee Less

1 week ago
LUPUS EUROPE

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. ๐Ÿงก

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Letโ€™s work together and lift each other up.
... See MoreSee Less

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. ๐Ÿงก

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Letโ€™s work together and lift each other up.
2 weeks ago
LUPUS EUROPE

Good news!!! Belimumab, a monoclonal antibody, has been approved by the FDA for the treatment of pediatric patients with active lupus nephritis on standard therapy.

Belimumab is the first treatment specifically approved for lupus in more than 50 years.

You can read more about it, plus the results of the phase II, in the link from MedPage Today ๐Ÿ‘‡

www.medpagetoday.com/rheumatology/lupus/99927
... See MoreSee Less

Comment on Facebook

๐Ÿ’œ

Yes!!!!!!

nu hopen dat Nederland artsen dit overneemt๐Ÿค”

So happy to hear this

Brilliant

View more comments